ATE330589T1 - Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege - Google Patents

Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege

Info

Publication number
ATE330589T1
ATE330589T1 AT01976492T AT01976492T ATE330589T1 AT E330589 T1 ATE330589 T1 AT E330589T1 AT 01976492 T AT01976492 T AT 01976492T AT 01976492 T AT01976492 T AT 01976492T AT E330589 T1 ATE330589 T1 AT E330589T1
Authority
AT
Austria
Prior art keywords
treatment
pharmaceutical composition
composition containing
inflammatory diseases
respiratory tract
Prior art date
Application number
AT01976492T
Other languages
English (en)
Inventor
Louise Elizabeth Donnelly
Peter John Barnes
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Application granted granted Critical
Publication of ATE330589T1 publication Critical patent/ATE330589T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01976492T 2000-10-19 2001-10-19 Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege ATE330589T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/694,108 US6878751B1 (en) 2000-10-19 2000-10-19 Administration of resveratrol to treat inflammatory respiratory disorders

Publications (1)

Publication Number Publication Date
ATE330589T1 true ATE330589T1 (de) 2006-07-15

Family

ID=24787430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01976492T ATE330589T1 (de) 2000-10-19 2001-10-19 Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege

Country Status (12)

Country Link
US (1) US6878751B1 (de)
EP (1) EP1326595B1 (de)
AT (1) ATE330589T1 (de)
AU (1) AU2001295760A1 (de)
CA (1) CA2425420C (de)
CY (1) CY1107498T1 (de)
DE (1) DE60121012T2 (de)
DK (1) DK1326595T3 (de)
ES (1) ES2266271T3 (de)
PT (1) PT1326595E (de)
WO (1) WO2002032410A2 (de)
ZA (1) ZA200302727B (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039557A1 (en) * 2001-11-02 2003-05-15 The Regents Of The University Of California Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
US20070218151A1 (en) * 2002-03-12 2007-09-20 Universidade Do Estado Do Rio De Janeiro Process for obtention of decoctions of Vitis labrusca and Vitis vinifera skins
DE60216242T2 (de) * 2002-06-06 2007-05-24 Chiesi Farmaceutici S.P.A. Lösung von Wirkstoffen in HFA-Treibgasen mittels Emulsionen
BR0311772A (pt) * 2002-06-13 2007-05-08 Wyeth Corp inibidores da atividade do gene inflamatório e da biossìntese do colesterol
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
AU2003279070A1 (en) * 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2004105769A1 (en) * 2003-05-28 2004-12-09 Universite De Liege Pharmaceutical composition for the treatment and/or the prevention of atherosclerosis from infectious origin
CA2541590A1 (en) * 2003-10-10 2005-04-21 Resverlogix Corp. Treatment of diseases associated with the egr-1 enhancer element
WO2005069998A2 (en) * 2004-01-20 2005-08-04 Brigham Young University Technology Transfer Office Novel sirtuin activating compounds and methods for making the same
JP5140416B2 (ja) * 2004-06-21 2013-02-06 ユニヴァーシティー オブ ミシシッピ 望ましい化学的官能基を有する抗がん及び抗原虫ジヒドロアーテミシニン及びジヒドロアーテミシテンダイマー
EP1859040A2 (de) * 2005-02-25 2007-11-28 Isis Pharmaceuticals, Inc. Auf il-4r gerichtete zusammensetzungen und deren verwendungen
WO2006102407A2 (en) 2005-03-23 2006-09-28 Children's Medical Center Corporation Orthotic device for preventing and/or correcting deformational posterior plagiocephaly
WO2006127987A2 (en) * 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060293261A1 (en) * 2005-06-24 2006-12-28 Taisho Pharmaceutical Co., Ltd. Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli
AU2006269459B2 (en) * 2005-07-07 2013-02-07 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
CA2624796A1 (en) * 2005-10-03 2007-04-12 Isis Pharmaceuticals, Inc. Combination therapy using budesonide and antisense oligonucleotide targeted to il-4 receptor alpha
CA2631492A1 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
WO2007076366A2 (en) * 2005-12-20 2007-07-05 Isis Pharmaceuticals, Inc Double stranded nucleic acid molecules targeted to il-4 receptor alpha
EP1962869B1 (de) * 2005-12-21 2013-03-20 SolAeroMed Inc. Behandlung von atemwegserkrankungen
US20070207201A1 (en) * 2006-03-06 2007-09-06 Wyeth Liquid and Semi-Solid Pharmaceutical Formulations and Processes
FR2898493B1 (fr) * 2006-03-16 2008-08-08 Af Consulting Compositions cosmetiques, pharmaceutiques, alimentaires et veterinaires dont l'action d'activation de genes de type sirtuin permet de retarder le vieillissement des mammiferes et ses effets nefastes
ATE464890T1 (de) * 2006-03-28 2010-05-15 Epitech Group Srl Eine pharmazeutische zusammensetzung zur behandlung von pathologien, die durch die allgemeine immunantwort verursacht werden
US8524654B2 (en) * 2007-05-21 2013-09-03 The Uab Research Foundation Prolyl endopeptidase inhibitors for reducing or preventing neutrophilic inflammation
WO2009021022A2 (en) * 2007-08-06 2009-02-12 University Of Florida Research Foundation, Inc. Modulating the activity of nuclear receptors in order to treat hypoxia-related disorders
EP2185112A4 (de) * 2007-08-21 2012-01-18 Harbor Biosciences Inc Stabilisierte therapeutische zusammensetzungen und formulierungen
US20120183524A1 (en) * 2007-12-21 2012-07-19 University Of Rochester Molecular targets for treatment of inflammation
ME03529B (de) 2008-01-11 2020-04-20 Reata Pharmaceuticals Inc Synthetische triterpenoide und anwendungsverfahren bei der behandlung von erkrankungen
GB0801032D0 (en) * 2008-01-21 2008-02-27 Univ York Immune modulation
EP2259782A4 (de) * 2008-03-03 2013-01-23 Nad Life Pty Ltd Pharmazeutische formulierungen von resveratrol und verfahren zur ihrer anwendung bei der behandlung von zellerkrankungen
CN102083442B (zh) 2008-04-18 2014-08-13 里亚塔医药公司 抗氧化剂炎症调节剂：在c-17具有氨基和其它修饰的齐墩果酸衍生物
SI2271658T1 (sl) 2008-04-18 2017-03-31 Reata Pharmaceuticals, Inc. Antioksidantni modulatorji vnetja: C-17 homologirani derivati oleanolne kisline
EP2279197B1 (de) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidationsmittel als entzündungsmodulierende substanz: im c-ring gesättigte oleanolsäurederivate
CA2721665C (en) * 2008-04-18 2017-01-24 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
US20090307669A1 (en) * 2008-06-06 2009-12-10 Garst Jr Gerald Blaine Memory management for closures
ES2449396T3 (es) 2008-07-22 2014-03-19 Trustees Of Dartmouth College Cianoenonas monocíclicas y métodos de uso de las mismas
ES2362065B1 (es) * 2009-12-15 2012-05-18 Consejo Superior De Investigaciones Cient�?Ficas (Csic) Compuestos con actividad antiinflamatoria.
EP2558105B1 (de) 2010-04-12 2019-11-20 Reata Pharmaceuticals, Inc. Bardoxolon-methyl zur behandlung von obesität
CN101791292A (zh) * 2010-04-13 2010-08-04 江庆澜 虎杖苷喷雾剂在作为哮喘治疗药物中的应用
US20120121730A1 (en) * 2010-10-07 2012-05-17 Trinity Laboratories, Inc. Pharmaceutical and nutraceutical compositions for treating respiratory disease and associated phlegm
CA2822071C (en) 2010-12-17 2019-07-16 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
US10308599B2 (en) 2011-01-03 2019-06-04 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10647668B2 (en) 2011-01-03 2020-05-12 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US11407713B2 (en) 2011-01-03 2022-08-09 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US10273205B2 (en) 2011-01-03 2019-04-30 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US8933119B2 (en) 2011-01-03 2015-01-13 The William M. Yarbrough Foundation Method for treating phytophotodermatitis
US11279674B2 (en) 2011-01-03 2022-03-22 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
HUE044081T2 (hu) 2011-03-11 2019-09-30 Reata Pharmaceuticals Inc C4 Monometil-triterpenoid-származékok, és módszerek azok alkalmazására
BR112014026640B1 (pt) 2012-04-27 2021-05-18 Reata Pharmaceuticals, Inc compostos derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimórficas, composição farmacêutica, e uso dos mesmos
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
US10080734B2 (en) 2012-07-26 2018-09-25 The William M. Yarbrough Foundation Method for treating autism and other neurodevelopmental disorders
US9949943B2 (en) 2012-07-26 2018-04-24 The William M. Yarbrough Foundation Method for treating neurodegenerative diseases
US8865772B2 (en) 2012-07-26 2014-10-21 The William M. Yarbrough Foundation Method for treating skin cancer
US9839621B2 (en) 2012-07-26 2017-12-12 The William M. Yarbrough Foundation Method for treating bladder cancer
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
RS59194B1 (sr) 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkandiilni i alkendiilni derivati oleanolne kiseline i metode za njihovu upotrebu
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
CN105101958B (zh) * 2013-01-15 2019-05-17 纽斯尔特科学公司 治疗肺病状
CN113350324A (zh) 2013-08-21 2021-09-07 协和大学 树状聚合物-白藜芦醇复合物
US10667627B2 (en) 2015-05-05 2020-06-02 Children's Medical Center Corporation Devices and methods for supporting and containing premature babies and small-for-age infants
BR112018005861B1 (pt) 2015-09-23 2022-11-22 Reata Pharmaceuticals, Inc Compostos derivados de ácido oleanólico modificado com c4 para a inibição de il-17, composição farmacêutica e usos terapêuticos dos ditos compostos
ES2673942B1 (es) * 2016-11-23 2019-04-09 Consejo Superior Investigacion Compuestos acilados para el tratamiento de patologias oculares
WO2019246461A1 (en) 2018-06-20 2019-12-26 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
CN115135317A (zh) 2020-01-22 2022-09-30 西洛斯治疗有限公司 减少nmda拮抗剂的副作用
EP4019013A1 (de) 2020-12-24 2022-06-29 Bionotus GCV Behandlung von lungenerkrankungen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1577196A (en) * 1977-06-03 1980-10-22 Ile De France Compositions containing erythromycin and metoclopramide
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
US5411986A (en) 1993-03-12 1995-05-02 The Johns Hopkins University Chemoprotective isothiocyanates
IT1276225B1 (it) 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US5972995A (en) 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
US6414037B1 (en) 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
US6022901A (en) 1998-05-13 2000-02-08 Pharmascience Inc. Administration of resveratrol to prevent or treat restenosis following coronary intervention
ES2258337T3 (es) 1998-09-08 2006-08-16 Cornell Research Foundation, Inc. Uso de inhibidores de la ciclooxigenasa-2 para el tratamiento de enfermedades inflamatorias de cabeza y cuello.
EP1140050B1 (de) 1998-12-24 2003-12-03 1333366 Ontario Inc. Zusammensetzung zur behandlung von periodontalen erkrankungen
PE20010540A1 (es) 1999-07-30 2001-05-15 Procter & Gamble Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza
IT1318425B1 (it) 2000-03-24 2003-08-25 D B P Dev Biotechnological Pro Impiego del resveratrolo per il trattamento di eczema desquamativo,acne e psoriasi.

Also Published As

Publication number Publication date
EP1326595A2 (de) 2003-07-16
EP1326595B1 (de) 2006-06-21
WO2002032410A3 (en) 2002-08-01
DE60121012D1 (de) 2006-08-03
ZA200302727B (en) 2004-04-08
US6878751B1 (en) 2005-04-12
WO2002032410A2 (en) 2002-04-25
AU2001295760A1 (en) 2002-04-29
DK1326595T3 (da) 2006-10-23
PT1326595E (pt) 2006-09-29
CY1107498T1 (el) 2013-03-13
CA2425420A1 (en) 2002-04-25
DE60121012T2 (de) 2007-01-04
ES2266271T3 (es) 2007-03-01
CA2425420C (en) 2010-10-12

Similar Documents

Publication Publication Date Title
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
RU2004122921A (ru) Композиция для ингаляции
CY1122533T1 (el) Ανακινρα για χρηση στην αντιμετωπιση συνδρομου αποφρακτικης βρογχιολιτιδας
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
HUS1900056I1 (hu) Légzési rendellenességek kezelésére alkalmas, glikopirrolát tartalmú száraz porkészítményt tartalmazó inhaláló készülék és alkalmazása
ATE361077T1 (de) Indanylderivate zur behandlung von atemwegserkrankungen
BR0008699A (pt) Combinações de formoterol e furoato demometasona para asma
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
DE60030844D1 (de) Kombinationen von formoterol und tiotropium-salz
DE60216588D1 (de) Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
RU2006132036A (ru) Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей
JP2008533072A5 (de)
HRP20120286T1 (hr) Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti
NO20054767L (no) Sammensetninger omfattende apomorfin for inhalering i lunge
AR039409A1 (es) Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso.
SG137859A1 (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
JP2008115167A (ja) トラネキサム酸を含有する気道杯細胞過形成抑制剤
EA200701077A1 (ru) Применение конъюгатов липидов при лечении заболеваний
EA200500864A1 (ru) Новый, содержащий тиотропий порошковый препарат для ингаляции
BR0308984A (pt) Formulações em pó adequadas para inalação
JP2009506029A5 (de)
WO2007046113A3 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
JP2010189301A (ja) 新型インフルエンザ感染症に対する医薬組成物およびその利用
ATE475409T1 (de) Mikroemulsionsformulierungen mit bestimmten substanz p antagonisten
JP2009007332A (ja) アゼラスチン類とエフェドリン類を含有する医薬組成物

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1326595

Country of ref document: EP